Post Content

Before drug manufacturers ship vaccines to distributors they, along with the Food and Drug Administration (FDA), always test them to determine that they meet all safety and efficacy standards. As part of its quality assurance program, manufacturer Sanofi Pasteur, performs additional routine, ongoing tests of their flu vaccines to ensure that they continue to meet required specifications after they have been distributed health care providers.

This week, after performing these tests, Sanofi Pasteur notified Centers for Disease Control (CDC) and the FDA that the antigen content in a batch (known as a "lot") of syringes intended for children 6 months through 35 months of age distributed to providers in November, had dropped below a pre-specified limit making them slightly less potent.

Consequently, Sanofi Pasteur tested additional lots and found that three others also had an antigen content that had fallen below pre-specified limits. This means that doses from these four vaccine lots no longer meet the specifications for antigen content. Therefore, Sanofi is conducting a voluntary recall of these affected lots and has asked providers to return any vaccine they may have from these lots to the manufacturer.

The affected vaccine met all specifications at the time of release and both CDC and FDA have determined that there are no safety concerns for children who received this vaccine. Parents of children who received vaccines from the recalled lots do not need to take any action other than make sure their child receives their second dose if they have not already. There is NO need to revaccinate children who have received vaccine from these lots. The antigen content in the affected lots of vaccine is only slightly below the specification limit and experts expect it to still be effective against the H1N1 flu.

This drop in antigen content below the required specification only occurred in Sanofi Pasteur’s pediatric H1N1 monovalent vaccine in 0.25 mL pre-filled syringes. The same vaccine packaged in other forms, such as pre-filled syringes for older children and adults and multi-dose vials, continue to meet specifications.

For additional information please see CDC’s Questions and Answers related to the withdrawn vaccine at http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm

We encourage all residents to utilize the comments section on this blog to engage with us and each other. While we cannot respond to every comment or question directly, we find them very helpful to understand your questions and concerns and plan for future posts.

Written By:


Communications Office

Recent Posts

Weekly Flu Report, December 12, 2014 posted on Dec 12

This week’s flu report shows a slight dip in rates of flu-like illness since last week’s report – which is entirely in keeping with the unpredictable nature of flu season. One thing we know for sure is that no matter what, the single best way to   …Continue Reading Weekly Flu Report, December 12, 2014

Highlights of the Public Health Council Meeting, December 10, 2014 posted on Dec 10

The December monthly meeting of the Public Health Council featured the consideration of one Determination of Need (DoN) request, two votes on final amendments to existing regulations, and an informational presentation to the Council on a key DPH community initiative. First, the Council took up   …Continue Reading Highlights of the Public Health Council Meeting, December 10, 2014

Make Toy Safety a Priority This Holiday! posted on Dec 8

Make Toy Safety a Priority This Holiday!

Finding the absolute perfect gift is one of the joyful pleasures of the holiday season. Nothing can beat witnessing the smiles and excitement of children as they unwrap their toys. We want toys that will truly impress the little ones. Yet, as we begin our   …Continue Reading Make Toy Safety a Priority This Holiday!